XML 72 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair value of financial instruments and investments - Convertible Notes and Rights Exchange Agreement (Details) - USD ($)
 12 Months Ended
Apr. 29, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Aug. 31, 2015
Financial assets and liabilities measured at fair value on recurring basis            
Deferred consideration payable     $ 0      
Payments on deferred consideration obligation     38,100,000      
Issuance of common stock related to rights exchange     150,528,000      
Contingent consideration payable   $ 239,900,000 240,400,000      
3.00% Convertible senior notes due 2022 | Convertible debt            
Financial assets and liabilities measured at fair value on recurring basis            
Principal   150,000,000 150,000,000     $ 150,000,000.0
Interest rate ( as a percent )           3.00%
1.50% Convertible senior notes due 2026 | Convertible debt            
Financial assets and liabilities measured at fair value on recurring basis            
Principal   287,500,000 287,500,000   $ 287,500,000  
Interest rate ( as a percent )         1.50%  
Significant other observable inputs (Level 2) | 3.00% Convertible senior notes due 2022 | Convertible debt            
Financial assets and liabilities measured at fair value on recurring basis            
Fair value of convertible notes   158,300,000 193,200,000      
Significant other observable inputs (Level 2) | 1.50% Convertible senior notes due 2026 | Convertible debt            
Financial assets and liabilities measured at fair value on recurring basis            
Fair value of convertible notes   305,300,000 394,900,000      
Development and Regulatory Milestones | Recurring basis            
Financial assets and liabilities measured at fair value on recurring basis            
Contingent consideration payable   139,300,000 139,200,000      
Development and Regulatory Milestones | Recurring basis | Significant unobservable inputs (Level 3)            
Financial assets and liabilities measured at fair value on recurring basis            
Contingent consideration payable   139,300,000 139,200,000      
Regulatory Milestones | Nonrecurring basis | Significant unobservable inputs (Level 3)            
Financial assets and liabilities measured at fair value on recurring basis            
Gain (loss) recognized on change in fair value on contingent consideration forfeited by Participating Rightholders     1,000,000.0      
Net Sales Milestones and Royalties | Recurring basis            
Financial assets and liabilities measured at fair value on recurring basis            
Contingent consideration payable   100,600,000 101,200,000      
Net Sales Milestones and Royalties | Recurring basis | Significant unobservable inputs (Level 3)            
Financial assets and liabilities measured at fair value on recurring basis            
Contingent consideration payable   $ 100,600,000 101,200,000      
Agilis            
Financial assets and liabilities measured at fair value on recurring basis            
Net sales amount $ 150,000,000.0          
Agilis | Minimum            
Financial assets and liabilities measured at fair value on recurring basis            
Product sales (as a percent) 2.00% 2.00%        
Agilis | Maximum            
Financial assets and liabilities measured at fair value on recurring basis            
Development milestone payment obligations   $ 60,000,000.0        
Priority review voucher amount   535,000,000.0        
Development milestone payment obligations, net of cancellation and forfeiture   20,000,000.0        
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture   361,000,000.0        
Net sales amount   $ 150,000,000.0        
Product sales (as a percent) 6.00% 6.00%        
Agilis | Development and Regulatory Milestones | Significant unobservable inputs (Level 3) | Commitments            
Financial assets and liabilities measured at fair value on recurring basis            
Contingent consideration payable- net sales milestones and royalties   $ 139,300,000 139,200,000 $ 290,500,000    
Agilis | Net Sales Milestones and Royalties | Significant unobservable inputs (Level 3) | Commitments            
Financial assets and liabilities measured at fair value on recurring basis            
Contingent consideration payable- net sales milestones and royalties   100,600,000 101,200,000 $ 65,800,000    
Non-collaborative Arrangement Transactions | Agilis            
Financial assets and liabilities measured at fair value on recurring basis            
Development milestone payment obligations   40,000,000.0 40,000,000.0      
Payments on deferred consideration obligation     2,400,000      
Rights Exchange Agreement            
Financial assets and liabilities measured at fair value on recurring basis            
Cash consideration payment under Rights Exchange Agreement     $ 36,900,000      
Issuance of common stock related to rights exchange (in shares)     2,821,176      
Issuance of common stock related to rights exchange     $ 150,500,000      
Transaction fees     2,000,000.0      
Rights Exchange Agreement | Development and Regulatory Milestones            
Financial assets and liabilities measured at fair value on recurring basis            
Contingent liability, cancellation and forfeiture $ 211,600,000          
Rights Exchange Agreement | Regulatory Milestones            
Financial assets and liabilities measured at fair value on recurring basis            
Amount of potential future milestone payments forfeited by Participating Rightholders     174,000,000.0      
Settled value of milestone payments     139,200,000      
Gain (loss) recognized on settlement of milestones     (11,300,000)      
Rights Exchange Agreement | Development Milestones            
Financial assets and liabilities measured at fair value on recurring basis            
Amount of potential future milestone payments forfeited by Participating Rightholders     37,600,000      
Settled value of milestone payments     37,600,000      
Gain (loss) recognized on settlement of milestones     $ 700,000      
Rights Exchange Agreement | Agilis            
Financial assets and liabilities measured at fair value on recurring basis            
Contingent liability, cancellation and forfeiture   $ 211,600,000